Clinical Trials Browser

Active not recruiting × Prostatic Neoplasms × Docetaxel × Clear all

NCT07344779 2026-04-03

ROAD

Active not recruiting

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Phase 2 Active not recruiting

40 enrolled 12 charts

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1 Active not recruiting

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT03218826 2025-10-30

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

23 enrolled 15 charts

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03517969 2025-10-20

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

73 enrolled 14 charts

Prostatic Neoplasms

NCT04140526 2025-05-23

PRESERVE-001

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT05676203 2025-02-17

ARASAFE

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT03230734 2024-09-27

RAPSON

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03700099 2024-04-15

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

Phase 2/3 Active not recruiting

11,992 enrolled

Prostatic Neoplasms

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Phase 3 Active not recruiting

788 enrolled 10 charts

Prostatic Neoplasms